Congratulations to Kat Truelson on her publication in DMID on apramycin activity against contemporary multidrug-resistant strains of Staphylococcus aureus

Kat had a very productive undergraduate experience in the laboratory while attending Boston University as an undergraduate. Her first author manuscript titled: "Evaluation of Apramycin Activity Against Methicillin-Resistant, Methicillin-Sensitive, and Vancomycin-Intermediate Staphylococcus aureus Clinical Isolates" was just accepted into Diagnostic Microbiology and Infectious Diseases,  more commonly referred to as DMID. Congratulations!  She found that apramycin was equally active against MSSA, MRSA, and VISA strains, and demonstrated rapid time-kill kinetics. This manuscript expands apramycin's known activity spectrum to include contemporaneous human clinical strains of multidrug-resistant carbapenem=resistant Enterobacteriaceae = CRE; Acinetobacter baumannii, and Pseudomonas aeruginosa, and now Staphylococcus aureus.   

We are very excited for Kat as she is moving this summer to the University of Chicago to work on a much beloved organism, Legionella pneumophila, in Howard Shuman's laboratory.